Caribou Biosciences to Participate in the BofA Securities 2026 Health Care Conference

Caribou Biosciences (Nasdaq: CRBU) announced that CEO Rachel Haurwitz, PhD, will participate in a fireside chat at the BofA Securities 2026 Health Care Conference on May 13, 2026 at 8:40am PT in Las Vegas.

Rhea-AI Summary

Caribou Biosciences (Nasdaq: CRBU) announced that CEO Rachel Haurwitz, PhD, will participate in a fireside chat at the BofA Securities 2026 Health Care Conference on May 13, 2026 at 8:40am PT in Las Vegas.

Webcast details and replay access are available via the company Events page; webcasts remain available for at least 30 days after the event.

Argus May 6 session

+1.04% close to close Open Argus

Details

News Market Reaction – CRBU

In the May 6 session, CRBU gained 1.04%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights Caribou’s participation in the BofA 2026 Health Care Conference, adding...

Analysis

This announcement highlights Caribou’s participation in the BofA 2026 Health Care Conference, adding investor visibility but no new clinical or financial data. Historically, the stock reacted more strongly to substantive events such as the RMAT designation on Mar 31, 2026 and detailed 2025 results on Mar 5, 2026. With shares near $1.91, below the 200-day MA, and prior insider net selling, future reactions are likely to hinge on concrete trial progress and regulatory milestones rather than conference appearances alone.

Key Figures

Share price: $1.91 24h price change: 2.14% 52-week range: Low $0.7301 / High $3.535 +5 more

Share price

$1.91

Pre-news current price for CRBU

24h price change

2.14%

Move over prior 24 hours before article

52-week range

Low $0.7301 / High $3.535

Positioned 45.97% below 52-week high

Today’s volume

1,245,605 shares

Versus 20-day average 1,499,965 shares

Market cap

$184,536,032

Equity value prior to conference news

Conference time

8:40 a.m. PT

BofA 2026 Health Care Conference session on May 13, 2026

Webcast availability

30 days

Replay available on company website after event

Cash balance

$142.8M

Cash, cash equivalents and marketable securities at 12/31/2025

Historical Context

5 past events · Latest: Mar 31

5 events

1. Mar 31

   Regulatory designation

   24h Move

   +10.5%

   FDA RMAT designation for CB-011 based on promising CaMMouflage trial data.

2. Mar 05

   Earnings and update

   24h Move

   +6.4%

   Full-year 2025 results with cash position and CAR-T pipeline progress details.

3. Feb 12

   Investor conferences

   24h Move

   +4.0%

   Announcement of management participation in upcoming investor conferences.

4. Feb 04

   Clinical data update

   24h Move

   +3.9%

   Late-breaking presentations with updated clinical and translational CAR-T data.

5. Dec 01

   KOL event

   24h Move

   -0.6%

   Planned in-person and virtual KOL event at ASH 2025 on vispa-cel.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

crispr, genome-editing

2 terms

crispr medical

"a leading clinical-stage CRISPR genome-editing biopharmaceutical company"

CRISPR is a gene‑editing technology that works like precise molecular scissors to change DNA in living cells. For investors, it matters because it can speed development of new therapies, lower research costs, and create valuable intellectual property, but it also carries scientific, regulatory, ethical, and commercial risks that can strongly affect the value and prospects of companies working with the technology.

genome-editing medical

"a leading clinical-stage CRISPR genome-editing biopharmaceutical company"

Genome-editing is a set of laboratory techniques that make deliberate, targeted changes to an organism’s DNA—like using a word processor to correct, insert, or delete letters in a long instruction manual. For investors it matters because these tools enable new therapies, crops, and diagnostics that can create high-value products and markets, while also bringing technical risk, regulatory review, and ethical debate that influence development timelines, costs, and potential returns.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BERKELEY, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz, PhD, Caribou’s president and chief executive officer, will participate in a fireside chat at BofA Securities 2026 Health Care Conference on May 13, 2026, at 8:40am PT in Las Vegas, Nevada.

For more information and a link to the webcast, visit the Events page on Caribou’s website. Webcasts will be available on the Caribou website for at least 30 days after the event.

About Caribou Biosciences, Inc.
Caribou is a clinical-stage CRISPR genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. Caribou’s chRDNA genome-editing technology enables superior precision to develop cell therapies that are armored to potentially improve activity against diseases. Caribou is focused on vispacabtagene regedleucel (vispa-cel) and CB-011 as off-the-shelf CAR-T cell therapies that have the potential to provide broad access and rapid treatment for patients with hematologic malignancies. Follow the company @CaribouBio and visit www.cariboubio.com.

Caribou Biosciences, Inc. contact:
Peggy Vorwald, PhD
investor.relations@cariboubio.com
media@cariboubio.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Caribou (CRBU) present at the BofA Securities 2026 Health Care Conference?

Caribou will present on May 13, 2026 at 8:40am PT in Las Vegas. According to Caribou, CEO Rachel Haurwitz will join a fireside chat; the session is part of the conference program and offered in-person with a webcast option for remote access.

How can investors watch the Caribou (CRBU) webcast for the May 13, 2026 fireside chat?

Investors can watch via the company Events page with a live webcast link. According to Caribou, the webcast will stream on the company website and a replay will remain available for at least 30 days after the event for on-demand viewing.

Who from Caribou (CRBU) will speak at the BofA 2026 Health Care Conference?

Rachel Haurwitz, PhD, Caribou’s president and CEO, will participate in the fireside chat. According to Caribou, she will represent the company on May 13, 2026, discussing corporate developments in a moderated session for investors and analysts.

Will the Caribou (CRBU) presentation at BofA 2026 include a replay or on-demand access?

Yes, a replay will be available for at least 30 days after the event on the company website. According to Caribou, webcasts are archived on the Events page so investors can access the presentation after the live session.

Where can I find more details about Caribou (CRBU) participation at the BofA Securities 2026 conference?

More details and the webcast link are posted on Caribou’s Events page on its website. According to Caribou, the Events page includes session timing, webcast access instructions, and replay availability for at least 30 days.